Boston Scientific Adds To Carotid Pipeline With Endotex Nexstent
This article was originally published in The Gray Sheet
Executive Summary
Patient enrollment for a clinical trial evaluating Boston Scientific's Filterwire distal protection device with Endotex Interventional Systems' Nexstent carotid stent should begin by year-end.
You may also be interested in...
Boston Scientific Extends EndoTex Purchase Option; NexStent Evaluated
EndoTex Interventional Systems is planning an early 2004 launch of its self-expanding NexStent carotid stent outside the U.S., using Boston Scientific as exclusive distributor under an extended agreement between the firms
Boston Scientific Extends EndoTex Purchase Option; NexStent Evaluated
EndoTex Interventional Systems is planning an early 2004 launch of its self-expanding NexStent carotid stent outside the U.S., using Boston Scientific as exclusive distributor under an extended agreement between the firms
Boston Scientific Looking To Expand Urology/Gynecology Product Offerings
Boston Scientific remains open to the possibility of making an acquisition in the urology or gynecology area to boost the current 8-10% rate of revenue growth.